Clinical Trial Update: Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluates lenalidomide plus melphalan in patients with previously untreated multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Melphalan (Melphalan)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED